{
    "nct_id": "NCT04148937",
    "official_title": "A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies",
    "inclusion_criteria": "* Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer\n* Participants must have stopped other forms of treatment for the cancer\n* In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study\n* Participants must not be pregnant, and must agree to use birth control\n* Participants must have progressed through or be intolerant to therapies with known clinical benefit\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids\n* Participant must not have cancer that has spread to the brain\n* Participant must not have received a vaccine within the last 30 days\n* Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery\n* Participant must not have an infection that is currently being treated",
    "miscellaneous_criteria": ""
}